ArticleProceedings (Baylor University. Medical Center)
Prognostic factors in prostatic leiomyosarcoma: a pooled analysis of 143 reported cases.
Article in Proceedings (Baylor University. Medical Center). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The enigma of leiomyosacoma of the prostate: insight into diagnosis, pathophysiology, prognosis, and treatment.Proceedings (Baylor University. Medical Center)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostatic leiomyosarcoma is a rare and aggressive malignancy with limited prognostic data. We performed a pooled analysis of 143 cases from 82 published reports to identify key prognostic markers. Results: The median age at diagnosis was 57 years (interquartile range [IQR] 22.5 years), and the median tumor size was 8 cm (IQR 7 cm). Spindle cell morphology was the predominant histologic subtype, observed in 48.3% of cases, with 80.1% of tumors classified as high-grade. Metastasis was present in 37.2% of patients, recurrence was present in 25.9%, and the overall mortality rate was 57.2%. Kaplan-Meier survival analysis demonstrated significantly reduced survival in patients with metastasis (13 vs 32 months, Conclusion: Metastasis and tumor recurrence are key predictors of mortality in prostatic leiomyosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.